COVIDITY / Scancell, University of Nottingham - LARVOL DELTA

Characterization of nsp1 Binding to the Viral RNA Leader Sequence of Severe Acute Respiratory Syndrome Coronavirus. (PubMed, Biochemistry) - "Nonstructural protein 1 (nsp1) of the severe acute respiratory syndrome coronavirus (SCOV1 and SCOV2) acts as a host shutoff protein by blocking the translation of host mRNAs and triggering their decay...Finally, mutations of the RNA stem-loop did not completely abolish RNA binding by nsp1, suggesting that an RNA secondary structure is more important for binding than the sequence itself. Understanding the nature of binding of nsp1 to viral RNA will allow us to understand how this viral protein selectively suppresses host gene expression."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVIDITY-001: A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection (clinicaltrials.gov) - P1 | N=80 | Active, not recruiting | Sponsor: Scancell Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

COVIDITY-001: A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Scancell Ltd | N=40 ➔ 80 | Trial completion date: Jun 2022 ➔ Dec 2022 | Trial primary completion date: Apr 2022 ➔ Dec 2022

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

COVIDITY-001: A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Scancell Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

COVIDITY-001: A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Scancell Ltd

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. (PubMed, BMJ) - "Increased risks of haematological and vascular events that led to hospital admission or death were observed for short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of most of these events were substantially higher and more prolonged after SARS-CoV-2 infection than after vaccination in the same population."

Clinical • Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Ischemic stroke • Myocardial Infarction • Novel Coronavirus Disease • Respiratory Diseases • Thrombocytopenia • Venous Thromboembolism

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. (PubMed, Lancet Infect Dis) - "Systemic and local side-effects after BNT162b2 and ChAdOx1 nCoV-19 vaccination occur at frequencies lower than reported in phase 3 trials. Both vaccines decrease the risk of SARS-CoV-2 infection after 12 days."

Adverse events • Clinical • Journal • Observational data • Gastroenterology • Genetic Disorders • Infectious Disease • Novel Coronavirus Disease • Obesity • Respiratory Diseases